Navigation Links
Penn Medicine researchers harness the immune system to fight pancreatic cancer
Date:9/24/2013

PHILADELPHIA -- Pancreatic cancer ranks as the fourth-leading cause of cancer death in the United States, and is one of the most deadly forms of cancer, due to its resistance to standard treatments with chemotherapy and radiation therapy and frequently, its late stage at the time of diagnosis. A group of researchers led by the University of Pennsylvania's Perelman School of Medicine and Abramson Cancer Center, in collaboration with scientists from the University of Pittsburgh and University of Washington, published results of a clinical trial in which the standard chemotherapy drug for this disease, gemcitabine, was paired with an agonist CD40 antibody, resulting in substantial tumor regressions among some patients with advanced pancreatic cancer. By using a novel, real-time imaging approach to monitor tumor response to the immunotherapy, the team also found differences how primary and metastatic disease sites shrank. Their work appears online this month in Clinical Cancer Research.

"We're now using imaging to understand the treatment heterogeneity that one can see in immunotherapy not all tumors within a patient's body react the same way, even in the face of powerful treatments, and now we have a way to follow these unique treatment responses in patients in real-time," said lead author Gregory Beatty, MD, PhD, an assistant professor in the division of Hematology/Oncology in the Abramson Cancer Center.

The report builds on preliminary results of findings in both humans and mice published in Science in 2011. The new approach exploits an immune reaction in the microenvironment of the patient's primary tumor by targeting an immune cell surface molecule CD40 to turn a type of white blood cell known as macrophages against the tumor by causing them to attack the stroma, the fibrotic supporting tissue of the tumor that acts as a defensive barrier to standard therapies. The treatment ate away at this stroma, ultimately causing substantial shrinkage
'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. The Australasian Academy of Dental Sleep Medicine (AustADSM) Provides Mini-Residency Programs for Post Graduates in the Dental Treatment of Snoring and Sleep Apnea
2. Medical Procedure or Commercial Commodity? Facing the Challenges of Corporate Medicine Business Practices in Plastic Surgery
3. QualityStar Will Present at the Annual Conference for the Society to Improve Diagnosis in Medicine
4. Chicago, IL Pre-Organized Prescription Medicine Packs Now Available From MedExPack.com
5. Regenerative Medicines: Bone and Joint Applications
6. Study in New England Journal of Medicine: Colonoscopy saves lives
7. European Nuclear Medicine / Radiopharmaceuticals Market Worth $1.6 Billion by 2017- New Report by MarketsandMarkets
8. Global Telemedicine and M-Health Convergence Market 2019 Forecast and Analysis in New Research Report at ReportsnReports.com
9. CareClix Provides Telemedicine Services to Leading Provider of Warehouse and Shipping Services, Davis Storage of Danville, Virginia
10. Women’s Comprehensive Clinic for Internal Medicine Now Open
11. Home Healthcare Market (Equipment, Service & Telehealth / Telemedicine) Worth $296 Billion by 2016 - New Report by MarketsandMarkets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... have made a brain-related discovery that could revolutionize ... This discovery opens up the possibility that environmental ... specific brain activity that the researchers have identified ... Journal of Neuroscience has just published a ... associate professor of psychology and his doctoral student ...
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... have identified the first genetic variant specifically associated ... accounting for around 10-15 per cent of all ... of the breast cancer sub-type, called invasive lobular ... causes of this particular kind of breast cancer, ... research, published today (Thursday) in the journal ...
(Date:4/17/2014)... According to a study published today in PLOS ... world where malaria is common can mount an immune ... them to avoid repeated bouts of high fever and ... in their bloodstream. The findings may help researchers develop ... by the malaria parasite. , Each year, approximately 200 ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2
... ... MILLS, Md., March 12 Medifast, Inc.,(NYSE: MED ) announced ... 31, 2007., Financial highlights included:, -- Annual revenues ... to the previous year,s fourth quarter; ...
... nodes could alter treatment approach, study suggests , , WEDNESDAY, ... tumors and tissue from patients with early-stage lung cancer ... say researchers at the Johns Hopkins Kimmel Cancer Center. ... approach for lung cancers, which recur within five years ...
... Call Scheduled for Thursday, March 13, 2008, LANCASTER, ... ) today reported financial results for the second quarter,ended ... weeks ended February 3, 2008 were,approximately $34.7 million. Net ... per share., Myron Levy, the Company,s Chairman and ...
... 12 Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), ... proprietary product candidates principally,for use in the hospital ... year ended December 31, 2007, and provided corporate ... and for 2008 to date., "During 2007, ...
... 12, 2008 (BRONX, NY) The unwanted activation ... in two kidney problems that are major causes of ... of Medicine of Yeshiva University have found. Their research, ... failure, is described in the March issue of Nature ...
... been awarded a five-year, $2.1 million grant from the ... of the National Institutes of Health (NIH), to continue ... on research careers. , The grant renews support that ... the training of 26 UI clinician-scientists in pediatrics. They ...
Cached Medicine News:Health News:Medifast Announces Year-end 2007 Financial Results 2Health News:Medifast Announces Year-end 2007 Financial Results 3Health News:Medifast Announces Year-end 2007 Financial Results 4Health News:Medifast Announces Year-end 2007 Financial Results 5Health News:Medifast Announces Year-end 2007 Financial Results 6Health News:Medifast Announces Year-end 2007 Financial Results 7Health News:Medifast Announces Year-end 2007 Financial Results 8Health News:Medifast Announces Year-end 2007 Financial Results 9Health News:Genetic Markers May Predict Lung Cancer Recurrence 2Health News:Herley Reports Second Quarter Results 2Health News:Herley Reports Second Quarter Results 3Health News:Herley Reports Second Quarter Results 4Health News:Herley Reports Second Quarter Results 5Health News:Herley Reports Second Quarter Results 6Health News:Herley Reports Second Quarter Results 7Health News:Herley Reports Second Quarter Results 8Health News:Herley Reports Second Quarter Results 9Health News:Herley Reports Second Quarter Results 10Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 2Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 3Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 4Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 5Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 6Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 7Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 8Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 9Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 10Health News:Novel discovery by Einstein scientists could lead to much-needed kidney failure treatment 2Health News:$2.1 million NIH grant advances U-Iowa child health research 2Health News:$2.1 million NIH grant advances U-Iowa child health research 3
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... 2010 MMRSS, which has been,expanding its geographic footprint over the past 5 years, announced the,opening of ... , , ... Thailand , Indonesia , Sri,Lanka , Bangladesh , Vietnam and UAE, has ... , , ...
... , SUNNYVALE, Calif. , Aug. 3 Accuray Incorporated ... field of radiosurgery, announced today it received Shonin approval from the Japanese ... Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive ... as the "CyberKnife® Radiosurgery System." , ...
Cached Medicine Technology:MMRSS now in Hong Kong, Singapore and Taiwan 2Accuray's CyberKnife® G4 System Receives Shonin Approval 2Accuray's CyberKnife® G4 System Receives Shonin Approval 3Accuray's CyberKnife® G4 System Receives Shonin Approval 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: